iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants

• Published in: BMJ open 2023-03, Vol.13 (3), p.e069314-e069314
• Main Authors: Namba, Fumihiko, Honda, Masakazu, Sakatani, Shun, Motojima, Yukiko, Kikuchi, Kayoko, Sako, Mayumi, Ogawa, Kunio, Mikami, Masashi, Kawada, Kou, Fukuoka, Noriyasu, Ueda, Keiko
• Format: Article
• Language: English
• Subjects: Acetaminophen - therapeutic use; acute renal failure; Administration, Intravenous; Analgesics; clinical pharmacology; Clinical trials; Congenital diseases; Coronary vessels; Creatinine; Drug dosages; Drug therapy; Ductus Arteriosus, Patent - drug therapy; Heart failure; Hemodynamics; Humans; Ibuprofen - therapeutic use; Indomethacin - adverse effects; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Intensive care; Multicenter Studies as Topic; neonatal intensive & critical care; neonatology; Newborn babies; Oliguria; Paediatrics; Premature babies; Premature birth; protocols & guidelines; Randomized Controlled Trials as Topic; Ultrasonic imaging; Urine; Veins & arteries
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-069314

IntroductionPatent ductus arteriosus (PDA) causes severe morbidity in premature infants. Although the use of indomethacin is the standard therapy for PDA, it is sometimes not applicable because of its adverse effects, such as renal and platelet dysfunctions. Paracetamol has emerged as an alternative to indomethacin owing to its excellent safety profile in infants. Of the recently reported case series and clinical trials on the use of paracetamol for PDA, there are few reports in Japan on paracetamol use in preterm infants. Furthermore, indications for the use of paracetamol for PDA have not been approved for use in PDA. While the safety of intravenous paracetamol therapy in case series of preterm infants treated for haemodynamically significant PDA (hsPDA) has been reported, studies which were conducted to compare paracetamol to indomethacin are limited. We, therefore, intend to investigate the hypothesis that intravenous administration of paracetamol has superior safety over indomethacin.Methods and analysisMulticentre open-label randomised controlled trial for intravenous administration of paracetamol for PDA in preterm infants. The inclusion criteria are (1) hsPDA, (2) gestational age from 24 to 34 weeks and birth weight (BW) from 500 to 2000 g, (3) enrolment between 24 hours and 7 days from birth and (4) obtaining parental consent. The primary outcome is renal dysfunction within 48 hours from the last dose of the study drug. Enrolled patients fulfilling all the inclusion criteria are randomly allocated to either intravenous paracetamol or intravenous indomethacin. This trial requires 110 patients.Ethics and disseminationThe clinical trial would follow Japan’s Clinical Trials Act. The trial protocol was approved by the Clinical Research Review Board of Saitama Medical University (approval number: 222001). A written informed consent would be obtained from one of the parents. The results are expected to be published in a scientific journal.Trial registration numberjRCTs031220386.Protocol version31 March 2022, version 1.0.